Desitin Arzneimittel GmbH has signed an exclusive License Agreement to commercialize an orphan drug being developed by AFT Pharmaceuticals, a specialist pharmaceutical company based in Auckland, New Zealand, to treat facial angiofibromas, a symptom of Tuberous Sclerosis Complex (TSC).

more information